Carbamazepine inhibits the potentiation by adenosine analogues of agonist induced inositolphosphate formation in hippocampal astrocyte cultures

Biol Psychiatry. 1996 Oct 1;40(7):563-7. doi: 10.1016/0006-3223(96)00031-5.


Carbamazepine (CBZ) resembles lithium in its beneficial effects in therapy and prophylaxis of affective disorders. Since lithium is presumed to act via an attenuation of the inositolphosphate/Ca(2+)-second messenger system, it is of particular interest whether or not CBZ might also have inhibitory effects on this type of signal transduction. CBZ is an antagonist of adenosine A1-receptor subtypes. We show here that activation of adenosine A1-receptors potentiates the phenylephrine induced formation of inositolphosphates in hippocampal astrocytes and that this potentiating effect is inhibited by CBZ at a therapeutically relevant concentration. These results indicate that CBZ can by antagonism of adenosine A1-receptors inhibit the inositolphosphate/Ca(2+)-signalling in neural pathways regulated by adenosine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / analogs & derivatives*
  • Adenosine / pharmacology
  • Animals
  • Animals, Newborn
  • Astrocytes / drug effects*
  • Carbamazepine / pharmacology*
  • Cells, Cultured
  • Drug Synergism
  • Hippocampus / drug effects*
  • Inositol Phosphates / metabolism*
  • Lithium Chloride / pharmacology
  • Neural Pathways / drug effects
  • Phenylephrine / pharmacology
  • Purinergic P1 Receptor Antagonists*
  • Rats
  • Receptors, Purinergic P1 / classification
  • Second Messenger Systems / drug effects
  • Signal Transduction / drug effects


  • Inositol Phosphates
  • Purinergic P1 Receptor Antagonists
  • Receptors, Purinergic P1
  • Phenylephrine
  • inositol 4-phosphate
  • Carbamazepine
  • Lithium Chloride
  • Adenosine